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Abstract. 
 
Background: Amyotrophic lateral sclerosis (ALS) is devastating, leading to paralysis and death. Disease onset 
begins pre-symptomatically through spinal motor neuron (MN) axon die-back from musculature at 47 days of 
age in the mutant superoxide dismutase 1 (mSOD1G93A) transgenic ALS mouse model. This period may be 
optimal to assess potential therapies. We previously demonstrated that post-symptomatic adipose-derived stem 
cell conditioned medium (ASC-CM) treatment is neuroprotective in mSOD1G93A mice. We hypothesized that 
early disease onset treatment could ameliorate neuromuscular junction (NMJ) disruption. 
Objective: To determine whether pre-symptom administration of ASC-CM prevents early NMJ disconnection. 
Methods: We confirmed the NMJ denervation time course in mSOD1G93A mice using co-labeling of 
neurofilament and post- synaptic acetylcholine receptors (AchR) by a-bungarotoxin. We determined whether 
ASC-CM ameliorates early NMJ loss in mSOD1G93A mice by systemically administering 200µl ASC-CM or 
vehicle medium daily from post-natal days 35 to 47 and quantifying intact NMJs through co-labeling of 
neurofilament and synaptophysin with a-bungarotoxin in gastrocnemius muscle. 
Results: Intact NMJs were significantly decreased in 47 day old mSOD1G93A mice (p < 0.05), and daily 
systemic ASC-CM prevented disease-induced NMJ denervation compared to vehicle treated mice (p < 0.05). 
Conclusions: Our results lay the foundation for testing the long-term neurological benefits of systemic ASC-
CM therapy in the mSOD1G93A mouse model of ALS. 
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 1. Introduction 
 
Motor neuron (MN) diseases are devastating, causing death of both upper MNs and lower MNs, paralysis and 
death. Amyotrophic lateral sclerosis (ALS) is the most common MN disease, affecting thousands of individuals 
at productive peaks in their lives (Brooks, Miller, Swash, & Munsat, 2000; Naganska & Matyja, 2011; Wijesekera 
& Leigh, 2009). Symptom onset is often subtle and easily undetected in early stages. Peripheral axonal die-back 
from target musculature begins pre-symptomatically, followed by MN cell death throughout the neuraxis (Chiu et 
al., 1995; Fischer et al., 2004; Haenggeli & Kato, 2002). 
Many treatments for ALS have been tried, largely without success. Riluzole and edaravone, are the only 
treatments approved by the Food and Drug Administration. Riluzole exhibits limited efficacy, providing only a 
few months of increased lifespan (Traynor, Alexander, Corr, Frost, & Hardiman, 2003), and evaluation of 
edaravone is ongoing (Sawada, 2017). Most ALS therapies have targeted central nervous system (CNS) MN 
survival; however, if peripheral axonal die-back continues without intervention, muscle denervation and paralysis 
persist. As such, both central and peripheral disease components may need to be targeted simultaneously. 
The stromal-vascular cell fraction of adipose tissue contains abundant adipose-derived stem cells (ASCs) (Bourin 
et al., 2013; Hong, Traktuev, & March, 2010). We have shown that ASCs are reparative in ischemia and other 
pathology via secretion of anti-apoptotic, anti-inflammatory, and pro-angiogenic growth fac- tors and cytokines 
(Rehman et al., 2004).  ASCs also secrete several neuroprotective growth factors (Wei, Du, et al., 2009; Wei, 
Zhao,  et  al.,  2009; Zhao et al., 2009). Benefits of ASC-secreted paracrine factors have been demonstrated in 
multiple pre-clinical animal models including hindlimb ischemia, diabetes, acute lung injury, brain ischemia, and 
ALS (Fontanilla et al., 2015). In rat neonatal brain hypoxia-ischemia, ASC-CM markedly reduced ischemic tissue 
injury in vivo, and decreased neuron death in vitro (Wei, Du, et al., 2009; Wei, Zhao, et al., 2009). Our data have 
extended these pre-clinical neuroprotective findings to the evaluation of ASC-CM in mSOD1G93A mice. In this 
model, post-symptomatic ASC-CM therapy reduced MN apoptosis and pro- longed lifespan (Fontanilla et al., 
2015). 
Peripheral axonal “die-back” remains a key aspect of ALS onset and progression,  causing  synaptic 
breakdown and neuromuscular junction (NMJ) denervation (Fischer et al., 2004; Frey et al., 2000). This process 
begins in mSOD1G93A mouse hindlimb muscles long before MN loss and symptom onset (Fischer et al., 2004; Frey 
 et al., 2000). Despite possible long- term effects on the disease, surprisingly little research has focused on therapies 
targeting early NMJ denervation. Understanding how to slow or reverse this process may be critical for 
preventing disease progression or extending lifespan. This study aimed to confirm the time window for NMJ 
denervation onset and determine whether systemic ASC-CM therapy could limit this process in the mSOD1G93A 
mouse model of ALS. 
 
2. Materials and methods 
 
2.1. Animals 
 
We utilized female mSOD1G93A ALS mice [B6SJL-Tg(SOD1*G93A)1Gur/J; Jackson Laboratories] (n = 16). 
Female wild-type (WT) mice served as controls (Jackson Laboratories, n = 9). For time course assessment of 
NMJ innervation, mSOD1G93A mice were euthanized with an over- dose of ketamine/xylazine at post-natal day 
35, 39, 43 and 47 (n = 3-4/timepoint). WT mice were euthanized at post-natal day 47 (n = 3). Once anesthetized, 
as determined by lack of response to toe pinch stimulus, transcardial perfusion was performed with 50 ml 
phosphate buffered saline (PBS, pH 7.4) followed by 4% paraformaldehyde in 0.1  M  PBS  for  tis- sue fixation. 
Once perfused, hindlimb gastrocnemius muscles were dissected and post-fixed for 40 min followed by transfer 
to 30% sucrose solution for cryoprotection and cryosectioning. In animals used for comparing ASC-CM therapy 
effects on NMJ innervation, mSOD1G93A mice (n = 3-4) were treated with ASC-CM or Basal Medium Eagle 
(BME) and the mice were euthanized and tissue prepared as described above at post-natal day 47. All use of 
animals in this study followed the Guidelines for the Institutional Care and Use of Animals of Indiana University 
School of Medicine. 
 
2.2. ASC-CM preparation and administration 
 
Human subcutaneous adipose tissue samples were obtained from lipoaspiration/liposuction procedures and 
prepared as previously described (Gu et al., 2013; Traktuev et al., 2008; Wang et al., 2014). In brief, 
human adipose tissue samples were digested in col- lagenase type I (Worthington Biochemical) for 1 
 hr at 37◦C, filtered with 100 µm and 70 µm filters, and centrifuged at 300 g for 5 min to separate 
stromal cells from adipocytes. The ASC pellet was treated with red blood cell lysis buffer for 5 min at 
37◦C, then centrifuged at 300 g for 5 min. The supernatant was discarded, and the cell pellet was 
resuspended in endothelial growth medium-2 MV (EGM-2-MV, Lonza) consisting of endothelial basal 
medium-2 (EBM-2), 5% fetal bovine serum (FBS), and the supplemental growth factors vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), epidermal growth factor 
(EGF), and insulin- like growth factor (IGF-1). ASCs (4 106 cells/cm2) were plated in T75 tissue 
culture flasks and incubated at 37◦C in 5% CO2. Fresh EGM2-MV was replaced the next day. ASCs 
were cultured to 80% confluence before passaging and freezing. Passage 4 ASCs were seeded at 5 104 
cells/cm2 and grown to 80% confluence, and then rinsed and each T75 flask was incubated with 10 ml 
of Basal Media Eagle (BME) containing 5 mM KCl for 24 hrs. Conditioned media was collected, 
centrifuged for 5 min to eliminate debris and then filtered through a 22µm micrometer sterile filter 
before freezing CM and BME in 1 ml aliquots for use in the study. Collection of human adipose tissue 
was approved by the Indiana University Institutional Review Board.  
For treatment, mSOD1G93A mice were randomly assigned to ASC-CM or vehicle treatment 
groups, and daily i.p. injections of 200µl ASC-CM or vehicle (Basal Medium Eagle, BME) were 
administered. Injections were started post-natal day 35 and continued to day 47. During treatment, the 
general health and overall behavior of the mice was regularly monitored by the investigators, animal 
facility veterinary staff and qualified veterinarians. Daily ASC-CM injections did not cause any 
observable outward physical or behavior changes in the mice or weight changes compared to vehicle 
treated mice during the course of the study. 
 
2.3 Tissue preparation 
 
Following perfusion, bilateral gastrocnemius and soleus muscles were dissected and prepared for 
cryosectioning. Following cryoprotection, right medial gastrocnemius muscle was isolated and placed in Tissue Tek 
 OCT medium and frozen at –80◦C. Embedded frozen muscle tissue was transferred to  a cryostat chamber before 
cryosectioning.  Prepared gastrocnemius tissue was serially sectioned at 20µm for immunofluorescent labeling of 
neuromuscular junctions and innervation. 
 
2.4 Microscopic imaging and NMJ analysis 
 
In brief, 8 serial sections separated by an interval of 100 µm were air-dried on Superfrost microscope slides 
(Fisher Scientific), and incubated in  donkey serum-based blocking buffer for 1 hr at room temperature. Next, 
the slides were incubated with primary antibodies against neurofilament (chicken anti-neurofilament, 1:500, 
Aves Inc.), which labels innervation, or synaptophysin (Alex 488-conjugated mouse anti-synaptophysin, 1:100, 
Millipore), which labels the neuromuscular  pre-synapse,  overnight  at 4◦C. 
Slides were then washed in PBS+0.1% Triton- X100 (PBST). The slides incubated with primary 
neurofilament antibody were then incubated with donkey anti-chicken Alex 488-conjugated sec- ondary 
antibody (Jackson Immunoresearch) and Alex 555-conjugated a-bungarotoxin (1:800, Life Technologies), 
which labels the post-synaptic acetyl- choline receptors (AchRs) of the NMJ, for 1 hr at room temperature. The 
slides incubated with Alex 488-conjugated primary antibody against synapto- physin were also incubated with 
Alex 555-conjugated a-bungarotoxin (1:800, Life Technologies) for 1 hr at room temperature. Afterward, all 
slides were prepared for microscopic fluorescent imaging. Five random high-power fields per section were 
selected for quantification of synaptophysin/a-bungarotoxin (4 sections) and neurofilament/a-bungarotoxin co- 
labeled NMJs (4 sections). Quantification of percent intact NMJs (yellow) was determined by an overlay of a-
bungarotoxin (red) and synaptophysin (green) or neurofilament (green). Denervated NMJs were defined by the 
presence of only a-bungarotoxin (red). Percent intact NMJs was calculated using the follow- ing formula: [number 
of intact NMJs (yellow) / total number of motor end plates (yellow + red)] 100.  All slides were coded by an 
uninvolved investiga- tor prior to analysis. Imaging was performed on an Olympus BX40 epifluorescent 
microscope and NMJ quantification was accomplished using NIH ImageJ software. 
 
 
 
 2.5 Statistical analysis 
 
Statistical analysis was accomplished via an ANOVA and the Student-Newman-Keuls post hoc test (Sokal & 
Rohlf, 1995) using GraphPad Prism 6.0 software (GraphPad, Inc). 
 
3 Results 
 
3.1 Gastrocnemius NMJ innervation significantly diminished between post-natal days 39 and 47 in 
mSOD1G93A mice 
 
Upon quantifying intact NMJs in the medial gastrocnemius of mSOD1G93A and WT mice, we found that a 
significant decrease in neurofilament/a- bungarotoxin co-localized NMJs occurred between post-natal days 35 
and 47 (p < 0.05) and days 39 and 47 in mSOD1G93A mice (p < 0.05, Fig. 1A). The results from this time course 
suggest this decrease is rapid in mSOD1G93A mice. 
 
3.2 Innervation of NMJs was preserved by ASC-CM treatment 
 
As our data showed intact NMJs were significantly decreased by post-natal day 47, we examined the effects of 
daily systemic ASC-CM therapy before and through this time period in mSOD1G93A mice. When ASC-CM or 
BME vehicle was administered daily between post-natal days 35 and 47, ASC-CM treated mSOD1G93A mice had 
significantly more neurofilament/a-bungarotoxin co-localized NMJs than vehicle treated mice, with co-
localization res- cued to WT levels (p < 0.05, Fig. 1B & D.) Likewise, synaptophysin-positive NMJs were 
significantly increased over vehicle treated mSOD1G93A mice at post-natal day 47 (p < 0.05, Fig. 1C & E). Images 
shown in Fig. 1D and E are representative of the reduced intact NMJs following vehicle treatment, and increased 
intact NMJs observed through both neurofilament and synaptophysin co-labeling with post-synaptic AchRs 
following ASC-CM therapy. 
 
  
4 Discussion 
 
Our findings support previous reports of pre- symptomatic mSOD1G93A mouse hindlimb muscle denervation 
(Fischer et al., 2004), and show that systemic ASC-CM therapy promoted intact NMJs. To our knowledge, this 
is the first study of  its  kind to demonstrate therapeutic efficacy on early disease onset in an ALS mouse model. 
Understanding how ASC-CM may be imparting these effects requires further investigation. Historically, 
therapeutic studies in ALS have emphasized motor neuron survival; however, accumulating evidence indicates 
ALS is non-cell autonomous in that onset and progression of the disease involves more than one cell type and 
various anatomical structures. Other central and peripheral components can clearly influence MN survival and 
disease progression (Bilsland, Nirmalananthan, Yip, Greensmith, & Duchen, 2008; Boillee et al., 2006; Clement 
et al., 2003; Hossaini et al., 2011; Zagami, Beart, Wallis, Nagley, & O’Shea, 2009). MN interaction with glial 
cells, skele- tal muscle, and immune cells can influence MN death in ALS (Martin & Chang, 2012; Murdock, 
Bender, Segal, & Feldman, 2015; Nardo et al., 2016; Pansarasa, Rossi, Berardinelli, & Cereda, 2014). These 
complex and dynamic interactions likely con- tribute to MN loss and early axonal die-back from the NMJ. 
Several mechanisms for pre-symptomatic mSOD1G93A axonal die-back have been proposed. Neuromuscular 
junction structure and transmission alterations are some of the earliest peripheral axonal dysfunctions in ALS 
(Fischer et al., 2004; Gurney et al., 1994; Rocha, Pousinha, Correia, Sebastiao, & Ribeiro, 2013). As MNs are 
functional during this early period, intrinsic metabolic changes could play a role in die-back. Autophagy and 
axonal transport dysregulation are associated with mutant SOD1- associated MN disease and synaptic integrity 
(Lee, Shin, Lee, & Choi, 2015). Upregulated autophagy has been shown to mitigate abnormal protein 
aggregation, enhance MN survival, and increase lifespan in ALS models (Lee et al., 2015; Rudnick et al., 2017), 
as well as possibly accelerate disease onset (Rudnick et al., 2017) which suggests that MN metabolic processes 
in ALS are complicated and that late and early disease stages are regulated differently. 
Our research has shown that ASC-secreted trophic factors including brain-derived neurotrophic factor (BDNF) 
and nerve growth factor (NGF) are neuroprotective (Wei, Du, et al., 2009; Kim et al., 2013). Blocking NGF prior 
to ASC-CM treatment in mSOD1G93A mice revealed it contributed to observed neuroprotective effects (Fontanilla 
et al., 2015). BDNF proved to be a key neuroprotective component of ASC-CM in experimental stroke therapy 
 (Wei, Du, et al., 2009). This suggests trophic factors in ASC-CM act centrally through crossing the blood 
brain/spinal cord barrier (BSCB). As the BSCB is compromised as early as 60 days of age in mSOD1G93A 
mice, this would allow proteins like trophic factors into the CNS (Zhong  et al., 2008). However, we did not 
examine peripheral tissues for therapeutic effects following late-stage treatment. Such peripheral effects are 
possible, as some functional improvement was observed follow- ing post-symptomatic ASC-CM ALS therapy. 
The central effects of BDNF have been widely studied, though it could also directly affect NMJ integrity.  
BDNF  acts  on  Trk   subtype  B   (TrkB) receptors, which are shown to preserve adult NMJ morphology and 
function (Mantilla et al., 2014). In addition, TrkB activity reduction induced presynaptic terminal restructuring 
and motor axon disruption. Since ASC-CM contains BDNF (Wei, Du, et al., 2009) and is neuroprotective within 
the CNS (Wei, Du, et al., 2009; Fontanilla et al., 2015), it could activate and enhance TrkB receptor function at the 
NMJ, strengthening axonal innervation and NMJ functional integrity. 
The present study cannot distinguish whether NMJ preservation by early ASC-CM therapy occurred through 
peripheral or central influence. Intraspinal transfection of MNs in mSOD1G93A mice with viral-mediated 
granulocyte colony stimulating factor (AAV-GCSF) reduced gastrocnemius NMJ denervation (Henriques et al., 
2011), indicating that centrally targeted therapies can positively influence NMJ integrity. 
In conclusion, we have confirmed the period of significant NMJ loss in mSOD1G93A mice, which aligns with 
prior studies. Importantly, our findings indicate ASC-CM prevents early disease pathology, which supports its 
use in familial ALS. These findings highlight the urgency for early identification in at-risk populations for 
developing ALS. A valuable time window is present long before symptoms start, and ASC-CM could potentially 
delay disease onset or progression. Further research is required to determine the site and mechanism of action and 
the influence of early benefits on long term neurological and survival outcomes. 
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Fig. 1. NMJ denervation time course and therapeutic effects of ASC-CM on NMJ loss. A) Quantification of neurofilament and a-bungarotoxin 
NMJs showed significant reduction in co-labeling between post-natal days 35 and 47, and post-natal days 39 and 47 (p < 0.05). B & D) At 
post-natal day 47, mSOD1G93A mice that were treated with daily i.p. vehicle showed significant loss of innervated NMJs as determined by 
neurofilament/a-bungarotoxin co-labeling compared to WT mice (p < 0.001). mSOD1G93A mice treated with ASC-CM showed significantly 
more co-labeled NMJs than vehicle treated mice (p < 0.05) at this time point. C & E) Similar results were observed for pre-synaptic 
synaptophysin co-labeling with a-bungarotoxin. Significantly fewer co-labeled NMJs were observed in vehicle treated mSOD1G93A mice 
than WT mice at post-natal day 47 (p < 0.01), while more co-labeling was observed with ASC-CM treatment compared to vehicle treatment 
(p < 0.05). ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001.
 
